No Data
No Data
New Analyst Forecast: $CNTX Given 'Outperform' Rating
William Blair Initiates Context Therapeutics(CNTX.US) With Buy Rating
William Blair Initiates Context Therapeutics at Outperform
Promising Outlook for Context Therapeutics: Buy Rating Backed by Innovative T-Cell Engagers and Strategic Pipeline Expansion
Express News | Context Therapeutics -Anticipates Sharing Initial Data for Ct-95 Phase 1 Trial in Mid-2026
Express News | Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of Ct-95